2023
Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis
Moledina D, Obeid W, Smith R, Rosales I, Sise M, Moeckel G, Kashgarian M, Kuperman M, Campbell K, Lefferts S, Meliambro K, Bitzer M, Perazella M, Luciano R, Pober J, Cantley L, Colvin R, Wilson F, Parikh C. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis. Journal Of Clinical Investigation 2023, 133: e168950. PMID: 37395276, PMCID: PMC10313360, DOI: 10.1172/jci168950.Peer-Reviewed Original ResearchConceptsUrinary CXCL9External validation cohortValidation cohortControl groupAIN diagnosisDiscovery cohortKidney tissueDiagnostic biomarkersAcute interstitial nephritisCXCL9 mRNA expressionAcute kidney injuryBiopsy-confirmed diagnosisAvailable clinical testsNational InstituteKidney injuryTubulointerstitial nephritisInterstitial nephritisKidney biopsyHistological confirmationHistological diagnosisTreatment optionsLymphocyte chemotaxisCXCL9MRNA expression differencesPatients
2022
Safety and Adequacy of Kidney Biopsy Procedure in Patients with Obesity
Qian L, Menez S, Hu D, Weinstein J, Melchinger H, Thiessen-Philbrook H, Luciano R, Turner J, Perazella M, Villalobos C, Shaw M, Wilson F, Parikh C, Moledina D. Safety and Adequacy of Kidney Biopsy Procedure in Patients with Obesity. Kidney360 2022, 4: 98-101. PMID: 36700910, PMCID: PMC10101611, DOI: 10.34067/kid.0006602022.Peer-Reviewed Original ResearchDiagnosis and management of immune checkpoint inhibitor-associated acute kidney injury
Sprangers B, Leaf DE, Porta C, Soler MJ, Perazella MA. Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury. Nature Reviews Nephrology 2022, 18: 794-805. PMID: 36168055, DOI: 10.1038/s41581-022-00630-8.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsAcute kidney injuryKidney injuryKidney biopsyAcute tubulo-interstitial nephritisImmune-related adverse eventsConcomitant anticancer therapyTubulo-interstitial nephritisEffector T cellsEvaluation of patientsLoss of toleranceCheckpoint inhibitorsPartial remissionPermanent discontinuationAdverse eventsMost patientsAppropriate treatmentEarly initiationT cellsClinical practiceFavorable responsePatientsAccurate diagnosisCancer treatmentAnticancer therapyImproving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials
Sprangers B, Perazella MA, Lichtman SM, Rosner MH, Jhaveri KD. Improving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials. Kidney International Reports 2022, 7: 1939-1950. PMID: 36090489, PMCID: PMC9458993, DOI: 10.1016/j.ekir.2022.06.005.Peer-Reviewed Original ResearchChronic kidney diseaseEnd-stage kidney diseaseSevere kidney dysfunctionKidney diseaseKidney dysfunctionAdvanced kidney diseaseOptimal clinical careCancer drug trialsNumber of patientsNarrow therapeutic indexInitial clinical studiesKidney replacement treatmentPreregistration studiesKidney functionCancer careReplacement treatmentCancer trialsClinical trialsEffective dosingClinical studiesTreatment decisionsDrug trialsBeneficial drugsClinical carePatientsUrine testing to differentiate glomerular from tubulointerstitial diseases on kidney biopsy
Tran AC, Melchinger H, Weinstein J, Shaw M, Kent C, Perazella MA, Wilson FP, Parikh CR, Moledina DG. Urine testing to differentiate glomerular from tubulointerstitial diseases on kidney biopsy. Practical Laboratory Medicine 2022, 30: e00271. PMID: 35465621, PMCID: PMC9018443, DOI: 10.1016/j.plabm.2022.e00271.Peer-Reviewed Original ResearchTubulointerstitial diseaseKidney biopsyGlomerular diseaseUrine albuminHistological diagnosisUrine uromodulinUrine testsHigher urine albuminUrine sediment microscopyCohort of participantsDipstick hematuriaTubular injuryAppropriate patientsUrine testingMultivariable modelHigher oddsBiopsyClinical decisionSediment microscopyDiseasePatientsHealth biomarkersUrine samplesDiagnosisCohort
2021
Development and external validation of a diagnostic model for biopsy-proven acute interstitial nephritis using electronic health record data
Moledina DG, Eadon MT, Calderon F, Yamamoto Y, Shaw M, Perazella MA, Simonov M, Luciano R, Schwantes-An TH, Moeckel G, Kashgarian M, Kuperman M, Obeid W, Cantley LG, Parikh CR, Wilson FP. Development and external validation of a diagnostic model for biopsy-proven acute interstitial nephritis using electronic health record data. Nephrology Dialysis Transplantation 2021, 37: 2214-2222. PMID: 34865148, PMCID: PMC9755995, DOI: 10.1093/ndt/gfab346.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisInterstitial nephritisUrine biomarkersBiopsy-proven acute interstitial nephritisElectronic health record dataExternal validation cohortTypical clinical featuresBlood urea nitrogenTumor necrosis factorCharacteristic curve analysisHealth record dataExternal validationElectronic health recordsAIN diagnosisModest AUCsSerum creatinineCreatinine ratioKidney biopsyClinical featuresValidation cohortNecrosis factorUnrecognized casesInterleukin-9PatientsUrea nitrogenCheckpoint inhibitor therapy-associated acute kidney injury: time to move on to evidence-based recommendations
Perazella MA, Sprangers B. Checkpoint inhibitor therapy-associated acute kidney injury: time to move on to evidence-based recommendations. Clinical Kidney Journal 2021, 14: 1301-1306. PMID: 33970161, PMCID: PMC8087122, DOI: 10.1093/ckj/sfab052.Peer-Reviewed Original ResearchAcute kidney injuryImmune checkpoint inhibitorsAcute tubulointerstitial nephritisKidney biopsyImmune-related adverse eventsVall d'Hebron University HospitalSingle-center studyNoninvasive diagnostic markerEvidence-based recommendationsAKI patientsICI rechallengeNephrology servicesCheckpoint inhibitorsICI treatmentKidney injuryAdverse eventsTubulointerstitial nephritisNonhematologic malignanciesUniversity HospitalTreatment protocolClinical practicePatientsOptimal managementDiagnostic markerCancer treatment
2020
Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation
Weinreb JC, Rodby RA, Yee J, Wang CL, Fine D, McDonald RJ, Perazella MA, Dillman JR, Davenport MS. Use of Intravenous Gadolinium-Based Contrast Media in Patients With Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Kidney Medicine 2020, 3: 142-150. PMID: 33604544, PMCID: PMC7873723, DOI: 10.1016/j.xkme.2020.10.001.Peer-Reviewed Original ResearchNephrogenic systemic fibrosisNational Kidney FoundationKidney diseaseGroup IIConsensus statementKidney FoundationAmerican CollegeRisk of NSFContrast mediumAcute kidney injuryAdvanced kidney diseaseCare of patientsGadolinium-based contrast mediaKidney injuryDialysis initiationClinical indicationsSystemic fibrosisPatientsIntravenous gadoliniumUnconfounded casesDiseasePotential harmRadiologyRiskFibrosisUse of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation
Weinreb JC, Rodby RA, Yee J, Wang CL, Fine D, McDonald RJ, Perazella MA, Dillman JR, Davenport MS. Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Radiology 2020, 298: 202903. PMID: 33170103, DOI: 10.1148/radiol.2020202903.Peer-Reviewed Original ResearchConceptsNephrogenic systemic fibrosisNational Kidney FoundationKidney diseaseGroup IIConsensus statementKidney FoundationAmerican CollegeRisk of NSFContrast mediumAcute kidney injuryAdvanced kidney diseaseCare of patientsGadolinium-based contrast mediaSimultaneous joint publicationKidney injuryDialysis initiationClinical indicationsSystemic fibrosisPatientsIntravenous gadoliniumUnconfounded casesDiseasePotential harmRadiologyRiskUrine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis
Moledina DG, Wilson FP, Kukova L, Obeid W, Luciano R, Kuperman M, Moeckel GW, Kashgarian M, Perazella MA, Cantley LG, Parikh CR. Urine interleukin-9 and tumor necrosis factor-α for prognosis of human acute interstitial nephritis. Nephrology Dialysis Transplantation 2020, 36: 1851-1858. PMID: 33125471, PMCID: PMC8476079, DOI: 10.1093/ndt/gfaa169.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisTumor necrosis factorCorticosteroid useIL-9Interstitial nephritisNecrosis factorAcute kidney injuryIL-9 levelsGlomerular filtration rateSubset of patientsCohort of participantsImmunosuppressive therapyTubulointerstitial infiltratesKidney injuryMedian eGFRKidney functionUrine biomarkersInterstitial fibrosisFiltration rateHistological featuresClinical trialsInterleukin-9PatientsEGFRComplete dataOnconephrology: The intersections between the kidney and cancer
Rosner MH, Jhaveri KD, McMahon BA, Perazella MA. Onconephrology: The intersections between the kidney and cancer. CA A Cancer Journal For Clinicians 2020, 71: 47-77. PMID: 32853404, DOI: 10.3322/caac.21636.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseDrug-induced nephrotoxicityKidney diseaseElectrolyte disordersAcute kidney injuryStem cell transplantationParaneoplastic glomerulonephritisKidney injuryCell transplantationTherapeutic regimensCollaborative careCancerDiseasePatientsOnconephrologyNew subspecialtySpecific training programsNephrotoxicityDisordersTraining programGlomerulonephritisRegimensNephrologistsTransplantationOncologistsIn Reply to ‘Contrast-Enhanced CT in Patients With Kidney Disease: Some Considerations in Response to the ACR/NKF Consensus’
Perazella MA, Weinreb JC, Davenport MS. In Reply to ‘Contrast-Enhanced CT in Patients With Kidney Disease: Some Considerations in Response to the ACR/NKF Consensus’. Kidney Medicine 2020, 2: 501. PMID: 32775994, PMCID: PMC7406849, DOI: 10.1016/j.xkme.2020.06.002.Peer-Reviewed Original ResearchNSAIDs in CKD: Are They Safe?
Baker M, Perazella MA. NSAIDs in CKD: Are They Safe? American Journal Of Kidney Diseases 2020, 76: 546-557. PMID: 32479922, DOI: 10.1053/j.ajkd.2020.03.023.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsNonsteroidal anti-inflammatory drugsChronic kidney diseaseGlomerular filtration rateFiltration rateRisk factorsHigh pain burdenAcute kidney injuryManagement of painAnti-inflammatory drugsCKD populationNSAID useKidney injuryPain burdenPain controlHeart failureComorbid conditionsElectrolyte derangementsKidney diseaseSafety dataDrug effectsPatientsIndividualized basisDrug metabolismProgressive lossCautious useHow to determine kidney function in cancer patients?
Sprangers B, Abudayyeh A, Latcha S, Perazella MA, Jhaveri KD. How to determine kidney function in cancer patients? European Journal Of Cancer 2020, 132: 141-149. PMID: 32361629, DOI: 10.1016/j.ejca.2020.03.026.Peer-Reviewed Original ResearchConceptsGlomerular filtration rateKidney functionCancer patientsDifferent glomerular filtration ratesAppropriate dose adjustmentCKD-EPI formulaSerum creatinine concentrationNarrow therapeutic indexDose adjustmentFiltration rateClinical trialsCreatinine concentrationTherapeutic indexAnti-cancer drugsPatientsToxic drugsDrugsBody surfaceTrialsImmune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
Herrmann SM, Perazella MA. Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events. Kidney International Reports 2020, 5: 1139-1148. PMID: 32775813, PMCID: PMC7403510, DOI: 10.1016/j.ekir.2020.04.018.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsAcute kidney injuryCheckpoint inhibitorsAdverse renal effectsAdverse renal eventsSubset of patientsPotential risk factorsAcute rejectionRenal eventsKidney injuryRenal effectsTransplant populationRenal toxicityRisk factorsBetter outcomesPatientsNephrotoxicityCliniciansCancer therapyCancerRecent studiesInhibitorsCurrent informationComplicationsProvidersThe kidney–cancer connection continues to grow
Perazella M. The kidney–cancer connection continues to grow. Journal Of Onco-Nephrology 2020, 4: 26-27. DOI: 10.1177/2399369320916474.Peer-Reviewed Original ResearchUse of Intravenous Iodinated Contrast Media in Patients With Kidney Disease Consensus Statements from the American College of Radiology and the National Kidney Foundation
Davenport MS, Perazella MA, Yee J, Dillman JR, Fine D, McDonald RJ, Rodby RA, Wang CL, Weinreb JC. Use of Intravenous Iodinated Contrast Media in Patients With Kidney Disease Consensus Statements from the American College of Radiology and the National Kidney Foundation. Kidney Medicine 2020, 2: 85-93. PMID: 33015613, PMCID: PMC7525144, DOI: 10.1016/j.xkme.2020.01.001.Peer-Reviewed Original ResearchAcute kidney injuryGlomerular filtration rateContrast mediumFiltration rateContrast-associated acute kidney injuryContrast-induced acute kidney injuryIntravenous normal salineReduced kidney functionSevere kidney diseaseNational Kidney FoundationIodinated Contrast MediaHigh-risk circumstancesCI-AKIKidney injuryMaintenance dialysisKidney functionKidney diseaseOrdering clinicianNormal salineConsensus statementKidney FoundationTreatment responseAmerican CollegePatientsControl groupUse of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation
Davenport MS, Perazella MA, Yee J, Dillman JR, Fine D, McDonald RJ, Rodby RA, Wang CL, Weinreb JC. Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation. Radiology 2020, 294: 192094. PMID: 31961246, DOI: 10.1148/radiol.2019192094.Peer-Reviewed Original ResearchConceptsAcute kidney injuryGlomerular filtration rateContrast mediumKidney diseaseFiltration rateContrast-associated acute kidney injuryContrast-induced acute kidney injuryIntravenous normal salineReduced kidney functionSevere kidney diseaseNational Kidney FoundationIodinated Contrast MediaHigh-risk circumstancesSimultaneous joint publicationCI-AKIKidney injuryMaintenance dialysisKidney functionOrdering clinicianNormal salineConsensus statementKidney FoundationTreatment responseAmerican CollegePatients
2019
Diagnosing acute interstitial nephritis: considerations for clinicians
Nussbaum E, Perazella M. Diagnosing acute interstitial nephritis: considerations for clinicians. Clinical Kidney Journal 2019, 12: 808-813. DOI: 10.1093/ckj/sfz080.Peer-Reviewed Original ResearchAcute interstitial nephritisAcute kidney injuryAcute tubular necrosisInterstitial nephritisCommon causeDirect further managementKidney injuryMost patientsTubular necrosisKidney biopsyClinical historyFurther managementCliniciansLaboratory dataNephritisPatientsInjuryDiagnosisSingle testCauseBiopsyNecrosisBiomarkersEvolution of the kidney–cancer connection
Perazella M, Workeneh B, Chen S. Evolution of the kidney–cancer connection. Journal Of Onco-Nephrology 2019, 3: 88-91. DOI: 10.1177/2399369319841616.Peer-Reviewed Original ResearchOnco-NephrologyKidney diseaseCare medicineMD Anderson Cancer CenterPalliative care medicineAnderson Cancer CenterCritical care medicineCancer CenterClinical pharmacologyClinical practiceAreas of medicineCancerDiseaseSpecialty groupsPatientsClinical medicineHighlights sectionMedicineTherapyNephrologyOncologyHematologyUrologyPharmacology